Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Proton-linked monocarboxylate transporter. Additionally we are shipping SLC16A4 Proteins (4) and many more products for this protein.
Showing 10 out of 16 products:
Elevated MCT4 protein expression in clinical prostate cancer specimens was associated with increases in Gleason grade, prolonged treatment of patients with neoadjuvant hormone therapy, castration resistant prostate cancer, and early disease relapse.
our finding that the expression of MCT1 (show CMA1 Antibodies) and MCT4 is reduced in mutant IDH1 (show IDH1 Antibodies) gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 (show IDH1 Antibodies) tumors and has important implications for our understanding of these tumors and their treatment
Results suggest that MCT4 plays a central role in tumor metabolism in gastric cancer (GC) with peritoneal carcinomatosis and targeting MCT4 in combination with chemotherapy could be a novel strategy in the treatment of GC.
TOMM20 (show TOMM20 Antibodies), MCT1 (show CMA1 Antibodies), and MCT4 expression was significantly different in Hodgkin and Reed Sternberg (HRS) cells. High MCT4 expression was found in tumor associated macrophages, but absent in HRS cells in all but one case. Tumor-infiltrating lymphocytes had absent MCT4 expression. Reactive lymph nodes in contrast to cHL (show CHRDL1 Antibodies) tumors had low TOMM20 (show TOMM20 Antibodies), MCT1 (show CMA1 Antibodies), and MCT4 expression in lymphocytes and macrophages.
Stromal cells in diffuse large B-cell lymphoma samples strongly expressed MCT4, displaying a glycolytic phenotype, a feature not seen in stromal elements of non-neoplastic lymphatic tissue.
MCT1 (show CMA1 Antibodies) inhibitor AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux.
The reversible H(+)/lactate(-) symporter MCT4 cotransports lactate and proton, leading to the net extrusion of lactic acid in glycolytic tumors. A model of its role in pH control in tumor cells is described. Review.
Increased miR (show MLXIP Antibodies)-210 and concomitant decreased ISCU (show ISCU Antibodies) RNA levels were found in ~40% of tumors and this was significantly associated with HIF-1alpha (show HIF1A Antibodies) and CAIX (show CA9 Antibodies), but not MCT1 (show CMA1 Antibodies) or MCT4, over-expression.
High expression of MCT4 is associated with inflammation in arsenite-induced liver carcinogenesis.
The loss expression of Cav-1 on CAFs and the up-regulation of MCT4 may be the possible mechanisms of CAFs in tumorigenesis.
This study showed that mouse MCT1 (show MCTS1 Antibodies), MCT2 (show SLC16A7 Antibodies), and MCT4 (show SLC16A3 Antibodies) are expressed in the PNS. While DRG neurons express MCT1 (show MCTS1 Antibodies), myelinating Schwann cells.
Expression of cerebral MCT (show MCAT Antibodies) isoforms can be modulated by alterations of peripheral metabolism, suggesting that the adult brain is sensitive and adapts to new metabolic states.
Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate (By similarity).
, MCT 5
, monocarboxylate transporter 4
, monocarboxylate transporter 5
, solute carrier family 16 (monocarboxylic acid transporters), member 4
, solute carrier family 16, member 4 (monocarboxylic acid transporter 5)
, solute carrier family 16, member 4
, LOW QUALITY PROTEIN: monocarboxylate transporter 5